EMA Recommends Extension of Therapeutic Indications for Acalabrutinib By Ogkologos - June 18, 2025 448 0 Facebook Twitter Google+ Pinterest WhatsApp A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR No Benefit for Post-operative Radiotherapy in Non-small-cell Lung Cancer [ESMO2020 Press... September 20, 2020 How We’re Working to Help People With Cancer Across the World April 7, 2021 Efficacy of Dabrafenib Plus Trametinib in First-Line Treatment for Children and... October 11, 2023 Her Wedding Ceremony Was Interrupted By A Voice In The Back,... March 25, 2019 Load more HOT NEWS Does Sugar Feed Cancer? First Prospective Description of Familial EGFR-mutated Lung Cancer UK sunburn risk: Third of adults more likely to protect their... Oligoprogression in Metastatic NSCLC Could Be Effectively Treated with SBRT Plus...
